{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:03:45Z","timestamp":1761566625760,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007273","name":"Weill Cornell Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007273","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jtho.2022.09.108","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T05:53:15Z","timestamp":1666936395000},"page":"e92-e93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to Dr. Goto\u2019s Letter: \u201cA Thymoma Mouse Model Harboring a Gtf2i L424H Mutation\u201d"],"prefix":"10.1016","volume":"17","author":[{"given":"Yongfeng","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"He","key":"10.1016\/j.jtho.2022.09.108_bib1"},{"key":"10.1016\/j.jtho.2022.09.108_bib2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.3016","article-title":"A\u00a0specific missense mutation in GTF2I occurs at high frequency in thymic\u00a0epithelial tumors","volume":"46","author":"Petrini","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2022.09.108_bib3","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3390\/cancers12082032","article-title":"Primary driver mutations in GTF2I specific to the development of thymomas","volume":"12","author":"Higuchi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2022.09.108_bib4","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1038\/s41418-020-0502-7","article-title":"Mutant GTF2I induces cell transformation and metabolic alterations in thymic epithelial cells","volume":"27","author":"Kim","year":"2020","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jtho.2022.09.108_bib5","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.09.108_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2022.09.108_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2022.09.108_bib8","article-title":"Molecular predictors of response to pembrolizumab in thymic carcinoma","volume":"2","author":"He","year":"2021","journal-title":"Cell. Reprod Med"},{"key":"10.1016\/j.jtho.2022.09.108_bib9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/13543784.2022.2113373","article-title":"Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials","volume":"31","author":"Conforti","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jtho.2022.09.108_bib10","first-page":"1092","article-title":"Sphingomonas and Phenylobacterium as major microbiota in thymic epithelial tumors","volume":"11","author":"Higuchi","year":"2021","journal-title":"J\u00a0Pers Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608642201694X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608642201694X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:49:58Z","timestamp":1761562198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155608642201694X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S155608642201694X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2022.09.108","relation":{},"ISSN":["1556-0864"],"issn-type":[{"type":"print","value":"1556-0864"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to Dr. Goto\u2019s Letter: \u201cA Thymoma Mouse Model Harboring a Gtf2i L424H Mutation\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2022.09.108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2022.09.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}